Navigation Links
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Date:10/16/2007

ade 3/4: 54%) and leukopenia (Grade 3/4: 49%).

(Phase III, Combination Trial: -046) The randomized Phase III trial evaluated the efficacy and safety of IXEMPRA in combination with capecitabine in comparison with capecitabine as monotherapy. This trial included 752 patients who were previously treated with anthracyclines and taxanes, and whose tumors had demonstrated prior resistance to these therapies. Anthracycline resistance is defined as progression while on therapy or within six months in the adjuvant setting, or three months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or four months in the metastatic setting. Evaluation of the primary endpoint demonstrated that IXEMPRA in combination with capecitabine resulted in a statistically significant improvement in progression-free survival compared to capecitabine monotherapy - median 5.7 (95% CI, 4.8-6.7) vs. 4.1 months (95% CI, 3.1-4.3); P<0.0001, Hazard ratio=0.69 (95% CI, 0.58-0.83).

Treatment-related non-hematological adverse events (greater than or equal to 20%) reported in patients treated with IXEMPRA in combination with capecitabine included: peripheral sensory neuropathy 65% (Grade 3/4: 21%), palmar-plantar erythrodysesthesia (hand-foot) syndrome 64% (Grade 3/4: 18%), fatigue/asthenia 60% (Grade 3/4: 16%), nausea 53% (Grade 3/4: 3%), diarrhea 44% (Grade 3/4: 6%), vomiting 39% (Grade 3/4: 4%), myalgia/arthralgia 39% (Grade 3/4: 8%), anorexia 34% (Grade 3/4: 3%), stomatitis/mucositis 31% (Grade 3/4: 4%), alopecia 31% (Grade 3/4: 0%), abdominal pain 24% (Grade 3/4: 2%), nail disorder 24% (Grade 3/4: 2%), musculoskeletal pain 23% (Grade 3/4: 2%), and constipation 22% (Grade 3/4: 0%). Treatment-related hematological adverse events (greater than or equal to 20%) reported in patients treated with IXEMPRA in combination with capecitabine included: neutropenia (Grade 3/4: 68%) and leukopenia (Grade 3/4: 57%).

Compa
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Analog people in the Digital Revolution, part II
9. Analog people in the digital revolution
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Spherix Incorporated (Nasdaq: SPEX ), an ... and atherosclerosis; and providers of technical and regulatory consulting ... announced that it will host an investment community conference ... December 9, to discuss results of the Company,s Phase ...
... 6, 2010 Viruses have a bad rep—and rightly ... precisely replicate itself makes it a destructive scourge to ... researchers at the University of Maryland,s A. James Clark ... Resources, brought together by Professor Reza Ghodssi, is turning ...
... Todd Hutchings has assumed leadership of Egon Zehnder ... who led the practice, will continue at the firm ... executives. In his new role, Mr. Hutchings ... with boards and providing the full array of functional ...
Cached Biology Technology:Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time 2Bad Virus Put to Good Use: Breakthrough Batteries 2Bad Virus Put to Good Use: Breakthrough Batteries 3Bad Virus Put to Good Use: Breakthrough Batteries 4Bad Virus Put to Good Use: Breakthrough Batteries 5Bad Virus Put to Good Use: Breakthrough Batteries 6Egon Zehnder International Names Todd Hutchings to Lead Life Sciences Practice Group 2
(Date:4/16/2014)... of Nicaragua,s legal, artisanal green sea turtle fishery has ... of turtles in what may have become an unsustainable ... Society and University of Florida. , During the research ... turtles were killed between 1991 and 2011, with catch ...
(Date:4/16/2014)... Florida State University researchers have identified a new ... bone density and muscle mass with obesity. , "It ... were the better your bones would be because the ... Hazel Stiebeling Professor of Nutrition at Florida State. "But, ...
(Date:4/16/2014)... eyes up, and you cannot lift your upper eyelid. You walk ... look straight when they are rolled down in the eye socket. ... normal position of their head. In order to correct this condition, ... paper published in the April 16 print issue of the journal ...
Breaking Biology News(10 mins):Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3Researchers: Obesity can amplify bone and muscle loss 2Researchers track down cause of eye mobility disorder 2
... as a model to study embryo formation, scientists report ... of a protein called Bicoid is vital to normal ... by the journal Dec. 19, the study shows how ... identified protein the researchers named Fates-shifted (Fsd). Without the ...
... Society has announced the winners of its second annual ... Annual Meeting at the Baltimore Convention Center in Baltimore, ... Professional Opportunities for Women, has initiated these travel fellowships ... their participation at the Meeting. The recipients of ...
... The prolonged, extensive emission of greenhouse gases over ... ocean life, according to a study by UC Merced ... emissions exacerbated by the burning of fossil fuels ... more acidic, and Beman,s study shows that the increased ...
Cached Biology News:Fruit fly study digs deeper into poorly understood details of forming embryos 2Biophysical Society announces winners of 2011 CPOW Travel Awards 2Rising greenhouse gases profoundly impact microscopic marine life 2
Newborn Calf Serum US Origin...
SPDP-Trinitrophenol (TNP) Bovine Serum Albumin...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
Biology Products: